急诊科静脉血栓栓塞症出院患者的抗凝治疗选择
该研究为加拿大安大略省一家三级中心急诊科的回顾性病历审查,纳入2019年1月至2021年12月急诊诊断深静脉血栓或肺栓塞并出院的成人(>17岁)患者。共确认390次急诊就诊、365例独特患者,其中239例(65.5%)出院并纳入分析。出院时70.7%(169/239)处方DOAC;癌症史与出院时使用LMWH而非DOAC相关(aOR=12.81,95%CI:6.60-25.90)。作者结论指出,尽管多数急诊VTE出院患者使用DOAC,但研究中多数癌症患者使用LMWH而非DOAC,尽管越来越多证据支持DOAC在多数癌症患者中的疗效与安全性。
要点
- 急诊诊断VTE并出院的239例患者中,70.7%(169/239)出院时处方DOAC。
- 癌症史与出院时使用LMWH而非DOAC独立相关(aOR=12.81,95%CI:6.60-25.90)。
- 纳入分析的239例中,12.1%年龄超过80岁,46.4%为女性,29.7%有癌症史。
- 作者认为,尽管越来越多证据支持DOAC在多数癌症患者中的疗效与安全性,但本研究中多数癌症患者仍使用LMWH而非DOAC。
适用人群与场景
- 加拿大安大略省一家三级中心急诊科,2019年1月至2021年12月急诊诊断深静脉血栓或肺栓塞并出院的成人(>17岁)患者。
研究设计与关键结果
- 研究类型:回顾性病历审查;单家三级中心急诊科;纳入2019年1月至2021年12月急诊诊断深静脉血栓或肺栓塞并出院的成人(>17岁)患者。
- 共确认390次急诊就诊、365例独特患者;其中239例(65.5%)出院并纳入分析。
- 纳入分析的239例中,12.1%年龄超过80岁,46.4%为女性,29.7%有癌症史。
- 出院时70.7%(169/239)处方DOAC。
- 癌症史与出院时使用LMWH而非DOAC相关(aOR=12.81,95%CI:6.60-25.90)。
证据类型、等级与局限
- 证据类型:回顾性病历审查。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,尽管越来越多证据支持DOAC在多数癌症患者中的疗效与安全性,但本研究中多数癌症患者使用LMWH而非DOAC。
- 作者建议需进一步研究以了解抗凝治疗的纵向趋势。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Direct oral anticoagulants (DOACs) are increasingly being used over low molecular weight heparin (LMWH) and vitamin K antagonists for the treatment of venous thromboembolism (VTE). The objective of this study was to examine predictors of anticoagulant type (DOAC vs. LMWH) prescribed at discharge from the emergency department (ED) among patients diagnosed with VTE in the ED.
METHODS: We conducted a retrospective chart review of adult (>17 years) patients discharged from an Ontario, Canada ED in a tertiary care centre with an ED diagnosis of deep vein thrombosis or pulmonary embolism from January 2019 to December 2021. A multivariable logistic regression model was used to examine the predictors of the anticoagulant (DOAC vs. LMWH) prescribed at discharge. Covariables included: age, sex, history of major bleeding, history of cancer, and previous anticoagulation.
RESULTS: VTE was confirmed in 390 ED visits by 365 unique patients. Among unique patients, 239 (65.5 %) patients were discharged from the ED and included in analysis. Of the 239 patients included, 12.1 % of patients were over the age of 80, 46.4 % were female and 29.7 % had a history of cancer. The majority of patients discharged from the ED were prescribed DOACs (70.7 %,169/239). Cancer history was associated with anticoagulation with LMWH (vs. DOAC) on discharge (adjusted odds ratio [aOR] =12.81, 95 % CI: 6.60-25.90).
CONCLUSIONS: While most patients diagnosed with VTE in the ED setting were discharged with DOACs, most cancer patients included in our study were treated with LMWH over DOACs, despite increasing evidence around the efficacy and safety of DOACs in most cancer patients. Further research is needed to understand longitudinal trends in anticoagulation.
参考来源
- Tandon P, Thompson C, Li K, et al. Anticoagulation for patients discharged from the emergency department with venous thromboembolism. Am J Emerg Med. 2025. PMID: 40222342. doi:10.1016/j.ajem.2025.04.009
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。